442847-52-1

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dichloro-7-(2-triMethylsilanyl-ethoxyMethyl)-7H-pyrrolo[2,3-d]pyriMidine is used as a potential pharmaceutical agent for its unique molecular structure that may interact with biological targets in novel ways, offering new avenues for drug development.
Used in Agrochemical Industry:
In the agrochemical sector, 2,4-Dichloro-7-(2-triMethylsilanyl-ethoxyMethyl)-7H-pyrrolo[2,3-d]pyriMidine may serve as a precursor or active ingredient in the development of new pesticides or herbicides, leveraging its specific chemical properties to control or manage agricultural pests and weeds.
Used in Materials Science:
2,4-Dichloro-7-(2-triMethylsilanyl-ethoxyMethyl)-7H-pyrrolo[2,3-d]pyriMidine is utilized in materials science for its potential to contribute to the development of new materials with unique properties, such as improved stability, reactivity, or selectivity in various chemical processes.

Upstream product

• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 90213-66-4 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine 
• 84955-31-7 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 7355-55-7 2-amino-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 

Downstream Products

• 1372263-17-6 2-{[4-((E)-2-{2-[ethyl(methylsulfonyl)amino]pyridin-3-yl}vinyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-N-methylbenzamide 
• 1372263-21-2 (E)-2-(4-(2-(2-(N-ethylmethylsulfonarnido)pyridin-3-yl)vinyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide 
• 1372263-36-9 N-(2-(((2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino)methyl)phenyl)-N-methylmethanesulfonamide 
• 1372262-47-9 ethyl 4-(4-(2-(N-methylmethylsulfonamido)benzylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzoate 
• 1372262-48-0 4-(4-(2(N-methylmethylsulfonamido)benzylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzoic acid 
• 1372263-46-1 N₄-benzyl-N₂-(2-methoxy-4-morpholinophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
• 1372262-49-1 4-(4-(2-(N-methylmethylsulfonamido)benzylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-(3-morpholinopropyl)benzamide 
• 1372262-45-7 4-{[4-({2-[methyl(methylsulfonyl)amino]benzyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-N-(3-morpholin-4-ylpropyl)benzamide 
• 1372262-88-8 N-(2-methoxy-4-morpholinophenyl)-4-(methylthio)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 1372262-89-9 N-(2-methoxy-4-morpholinophenyl)-4-(methylsulfonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 1372262-90-2 N-ethyl-N-(3-((2-(2-methoxy-4-morpholinophenylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl)pyridin-2-yl)methanesulfonamide 
• 1372262-84-4 N-ethyl-N-{3-[( {2-[(2-methoxy-4-morpholin-4-ylphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)methyl]pyridin-2-yl}methanesulfonamide 
• 1372262-46-8 N-(2-((2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl)phenyl)-N-methylmethanesulfonamide 
• 1557268-35-5 2-chloro-4-(3-nitrophenoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-D]pyrimidine 

Relevant academic research and scientific papers

An improved synthesis approach of the HIV-1 inhibitor RDEA427, a pyrrolo[2,3-d]pyrimidine derivative

The diarylpyrimidine-like derivative RDEA427 is a highly potent inhibitor against wild-type and a wide range of drug-resistant HIV-1 strains and has attracted much attention. However, the yield of its reported synthesis is too low and the route is less environment-friendly and uneconomic. In order to achieve a short and more economic synthesis of RDEA427, an investigation was carried out. The optimized synthesis approach of RDEA427 was accomplished in an increased overall yield (39%). Moreover, the new route is more environment-friendly and economic. This work will accelerate the drug discovery process.

HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF

The present invention relates to a heterocycle-fused pyrimidine derivative compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating diseases related to one or more protein kinases of FLT3, CDK4, CDK6 and HPK1, comprising the same as an active ingredient, and a method for preventing or treating diseases related to one or more protein kinases of FLT3, CDK4, CDK6 and using the same.

Pyrimidina-1,5(1,3)-dibenzenacycloheptaphane derivative as mutant epidermal growth factor receptor inhibitor

The present invention relates to a pyrimidinyl monobenzocycloheptazole derivative represented by chemical formula I, a solvate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient, capable of effectively inhibiting the growth and drug resistance of cancer cells caused by the mutation of tyrosine kinase domain in epidermal growth factor receptor (Chem. I). .

NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT

The present invention relates to a novel fused pyrimidine based sulfonamide derivative represented by Formula I, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same as an active ingredient. The novel fused pyrimidine based sulfonamide derivative of the present invention can effectively suppress the growth of cancer cells and resistance to drugs, which are induced by mutations in the tyrosine kinase domain of epidermal growth factor receptors, or the growth of cancer cells having such resistance.

CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with EGFR and/or HER2 activity.

Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity

TTK is an essential spindle assembly checkpoint enzyme in many organisms. It plays a central role in tumor cell proliferation and is aberrantly overexpressed in a wide range of tumor types. We recently reported on a series of potent and selective TTK inhibitors with strong antiproliferative activity in triple negative breast cancer (TNBC) cell lines (8: TTK IC50 = 3.0 nM; CAL-51 IC50 = 84.0 nM). Inspired by previously described potent tricyclic TTK inhibitor 6 (TTK IC50 = 0.9 nM), we embarked on a structure-enabled design and optimization campaign to identify an improved series with excellent potency, TTK selectivity, solubility, CYP inhibition profile, and in vivo efficacy in a TNBC xenograft model. These efforts culminated in the discovery of 25 (TTK IC50 = 3.0 nM; CAL-51 IC50 = 16.0 nM), which showed significant single-agent efficacy when dosed iv in a TNBC xenograft model without body weight loss.

HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a heteroaryl derivative and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient, and a compound according to an aspect of the present invention, a stereoisomer

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies

Two series of new pyridyl-bearing fused bicyclic analogues designed to target the dual-tolerant regions of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-binding pocket were synthesized and evaluated for their anti-HIV activities. Several comp

MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION

The present disclosure relates to chemical compounds that modulate cellular proliferation for the treatment of uncontrolled cellular proliferation disorders (such as cancer), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Oxy-fluoropiperidine Derivative as Kinase Inhibitor

The present invention relates to a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and the compound according to the present invention can be usefully used for the prevention or treatm ent of diseas